Alkermes Retains Neutral Rec - Analyst Blog

NEWS SEARCH ANALYSIS INSIGHT

Saturday, March 20, 2010 2:23 PM

Published Feb 08 2010 by Benzinga.com

Alkermes Retains Neutral Rec - Analyst Blog

We maintain our Neutral rating on Alkermes, Inc. ( ALKS ) with a price target of $11.50.

Alkermes is a drug delivery biotech company which uses its proprietary specialized drug delivery technologies to develop drugs for the treatment of central nervous system ( CNS ) disorders, alcoholism and diabetes.

Alkermes has two...

READ FULL ARTICLE

Share this

What others report on the same story

Alkermes Retains Neutral Rec - [Feb 09 2010 - Zacks.com]

Alkermes Retains Neutral Rec - Analyst Blog - [Feb 08 2010 - Benzinga.com]

First Reported Mar 18 2010 - Updated Mar 18 2010 - 2 Documents

FDA wants consumer questions, input

So how and when does the Food and Drug Administration decide to pull a prescription from the market?Should I be asking whether my doctor accepts gifts or sandwiches from drug companies? Why are drugmakers notified by the FDA when a device is harmful before ... [Published Mar 18 2010 by Chicago Tribune]

Entities: Food and Drug Administration, Task Force, Health Care, Vioxx

First Reported Mar 19 2010 - Updated Mar 19 2010 - 1 Documents

Food and Drug Administration

FDA Crack Down On Labelling Violations

US - Earlier this month, the US Food & Drug Administration (FDA) announced a major and broad initiative to increase FDA enforcement against illegal claims on food labelling, including unauthorized Nutrient Content Claims, health claims, and all drug and ... [Published Mar 19 2010 by Cattle Site]

Entities: Food and Drug Administration, Nutrient Content, Dietary Supplements

First Reported 19 hours ago - Updated 19 hours ago - 1 Documents

Alkermes Inc

Alkermes Pipeline Advances - Analyst Blog

Recently, Alkermes Inc. ( ALKS ) initiated a multidose early-stage study of its candidate of ALKS 37. ALKS 37 is an orally active, peripherally-restricted opioid antagonist, which has the potential to block the effects of opioid agonists on gastrointestinal ... [Published 19 hours ago by Benzinga.com]

Entities: Alkermes Inc, opioid, Tolerance

First Reported 22 hours ago - Updated 22 hours ago - 1 Documents

Janssen Pharmaceutica

Hear From Industry Reps [Annual Meeting]

Product theaters will again be held this year at APA's annual meeting. Featured in the theaters are promotional programs supported by exhibitors. Light refreshments will be available.Topics may include treatment management, disease updates, and issues ... [Published 22 hours ago by Psychiatric News]

Entities: Janssen Pharmaceutica, Alkermes Inc, American Psychiatric Association, Boehringer Ingelheim GmbH

First Reported 15 hours ago - Updated 15 hours ago - 1 Documents

Amylin Pharmaceuticals Inc

Mixed Grill Coming from the Clinics this Week

This week brought a mix of good news and bad news from the clinical trial front. Several companies and their shareholders are celebrating, and a few got no help. The FDA did issue a complete response letter to Lilly, Alkermes and Amylin with regard to ... [Published 15 hours ago by The Big Red Biotech Blog]

Entities: Alkermes Inc, Amylin Pharmaceuticals Inc, complete response

First Reported Mar 18 2010 - Updated Mar 18 2010 - 1 Documents

Twitter Inc

Twittering FDA - An Analysis of FDA's Twittering Activity

The Food and Drug Administration has been dipping its toe into the proverbial social media waters. In this space, I've encouraged FDA to become more involved in Facebook as a means of pushing information out to consumers rather than ... [Published Mar 18 2010 by Eye on FDA]

Entities: Food and Drug Administration, Twitter Inc, Animal Health International Inc, Center for Veterinary Medicine, Pharmacopeia Inc

First Reported Mar 18 2010 - Updated Mar 18 2010 - 1 Documents

FDA and Exponential Funding

FDA's $4.03 billion budget proposal for fiscal 2011 includes hiring 215 additional employees. Amidst all the details and hand-wringing there is a larger picture issue beginning to surface. In short: FDA will always lag far behind in terms of staffing. ... [Published Mar 18 2010 by Compliance Zen]

Entities: Food and Drug Administration, Personalized Medicine, Medical Devices, Biotechnology

Blogs

sort by: Date \| Relevance
Alkermes, Inc. F3Q10 (Qtr End 12/31/09) Earning... [Biotech Sector and Stocks Analysis from Seeking ... - Feb 05 2010] Alkermes, Inc. (ALKS) F3Q10 (Qtr End 12/31/09) Earnings Call February 4, 2010 at 4:30 pm ETComplete Story » ...
Few Comments Submitted to FDA Regarding Regulat... [Pharma Marketing Blog - Feb 11 2010] Although the FDA opened a docket on September 21, 2009, for public comment on regulating pharmaceutical company drug promotion on the Internet and social media (see ...
Outsourcing challenges FDA to strengthen oversi... [Spoonful of Medicine - Blog Posts - Feb 10 2010] Pharmaceutical companies are increasingly contracting out manufacturing to firms overseas as a way to trim their bottom line. But where pharma sees mostly cost-saving ...
More signs of life from the FDA [AMERICAblog News\| A great nation deserves the t ... - Feb 01 2010] The Obama FDA is worlds apart from the business-focused Bush FDA. It has to be one of the highlights of the Obama administration so far. If only we saw the same ...
Survey on the FDA, by David Henderson [EconLog - Feb 06 2010] I just finished filling out my survey on my views of the Food and Drug Administration's monopoly on approvals of drugs and medical devices. I was one of 305 economists ...

Audio/Video

sort by: Date \| Relevance
Dr. Margaret Hamburg - Director, FDA [USGOVHHS - YouTube Channel - Feb 04 2010]

Advanced Search Options

Alkermes Retains Neutral Rec - Analyst Blog

FDA wants consumer questions, input

FDA Crack Down On Labelling Violations

Alkermes Pipeline Advances - Analyst Blog

Hear From Industry Reps [Annual Meeting]

Mixed Grill Coming from the Clinics this Week

Twittering FDA - An Analysis of FDA's Twittering Activity

FDA and Exponential Funding